DRREDDY.NS - Dr. Reddy's Laboratories Limited
| Previous Close | 2,589.40 |
| Open | 2,594.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 2,594.00 - 2,699.95 |
| 52 Week Range | 1,872.95 - 2,964.00 |
| Volume | 2,008,134 |
| Avg. Volume | 679,415 |
| Market Cap | 443.255B |
| Beta (3Y Monthly) | 0.12 |
| PE Ratio (TTM) | 23.58 |
| EPS (TTM) | 113.09 |
| Earnings Date | May 10, 2018 - May 14, 2018 |
| Forward Dividend & Yield | 20.00 (0.68%) |
| Ex-Dividend Date | 2018-07-17 |
| 1y Target Est | 2,587.45 |
- Business Wire•5 days ago
Dr. Reddy’s Q4 & FY19 Financial Results
Dr. Reddy’s Laboratories Ltd. today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2019 under International Financial Reporting Standards .
- Simply Wall St.•7 days ago
Did You Miss Dr. Reddy's Laboratories's (NSE:DRREDDY) 40% Share Price Gain?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
- Business Wire•7 days ago
Dr. Reddy's Laboratories announces the launch of Daptomycin for Injection, 500mg/vial single-dose vial in the U.S. Market
Dr. Reddy’s Laboratories Ltd. today announced the launch of Daptomycin for Injection, 500mg/vial single-dose vial, a therapeutic equivalent generic version of Cubicin® for Injection, approved by the U.S.
- Business Wire•16 days ago
Dr. Reddy's Laboratories Announces the Launch of Testosterone Gel, 1.62% (20.25 mg/1.25 g Pump Actuation) in the U.S. Market
Dr. Reddy’s Laboratories Ltd. today announced the launch of Testosterone Gel 1.62%, a therapeutic equivalent generic version of AndroGel® 1.62%, approved by the U.S.
- Simply Wall St.•last month
Is Dr. Reddy's Laboratories Limited's (NSE:DRREDDY) CEO Overpaid Relative To Its Peers?
Gunupati Prasad became the CEO of Dr. Reddy's Laboratories Limited (NSE:DRREDDY) in 2001. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. Then...
- Business Wire•last month
Dr. Reddy's to Release Q4 and Full Year FY 19 Results on May 17, 2019
Earnings call slated for May 17, 6:00 PM IST / 8:30 AM EDT
- Business Wire•last month
Dr. Reddy's Laboratories Announces Acquisition of ANDA Portfolio
Dr. Reddy’s Laboratories Ltd. announced today that it has entered into a definitive agreement to acquire a portfolio of 42 approved, non-marketed Abbreviated New Drug Applications in the U.S.
- Business Wire•2 months ago
Promius Pharma, LLC. (a Wholly Owned Subsidiary of Dr. Reddy’s Laboratories Ltd.) Announces the Sale and Assignment of the US Rights for Its Marketed Dermatology Brands to Encore Dermatology
Dr. Reddy’s Laboratories Limited , through its wholly owned subsidiary Promius Pharma, LLC, announces the sale of its rights for SERNIVO® Spray, 0.05% and assignment of its rights to market and distribute, PROMISEB® Topical Cream and TRIANEX® 0.05% in the United States, to Encore Dermatology.
- Business Wire•2 months ago
Dr. Reddy's Laboratories launches Tadalafil Tablets USP in the U.S. Market
Dr. Reddy’s Laboratories Ltd. , along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Tadalafil Tablets USP, a therapeutic equivalent generic version of Cialis Tablets in the United States market, approved by the U.S.
- Simply Wall St.•2 months ago
Taking A Look At Dr. Reddy’s Laboratories Limited’s (NSE:DRREDDY) ROE
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use ReturnRead More...
- Business Wire•3 months ago
Dr. Reddy's Laboratories Announces the Re-Launch of Its Buprenorphine and Naloxone Sublingual Film after Favorable Ruling in Patent Litigation
Dr. Reddy’s Laboratories Ltd. along with its subsidiaries together referred to as “Dr. Reddy’s”) announced today the re-launch of its Buprenorphine and Naloxone Sublingual Film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg, a therapeutic equivalent generic version of Suboxone® sublingual film, in the United States market.
- Simply Wall St.•3 months ago
Who Has Been Buying Dr. Reddy’s Laboratories Limited (NSE:DRREDDY) Shares?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! We often see insiders buying up sharesRead More...
- Business Wire•4 months ago
Dr. Reddy's Laboratories Continues its Voluntary Nationwide Recall of Levetiracetam in 0.54% Sodium Chloride Injection 1500mg/100mL Due to Mislabeling
Dr. Reddy’s Laboratories Ltd. announced that its wholly owned subsidiary, Dr Reddy’s Laboratories, Inc, is continuing its voluntary nationwide recall of lot ABD807 of Levetiracetam in 0.54% Sodium Chloride Injection, 1,500 mg/100 mL single-dose infusion bags to the hospital level in U.S.A.
- Business Wire•4 months ago
Dr. Reddy's Announces the Appointment of Marc Kikuchi to Lead Its Generics Business in North America
Dr. Reddy’s Laboratories Ltd. , along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the appointment of Marc Kikuchi as Chief Executive Officer, North America Generics.
- Business Wire•4 months ago
Dr. Reddy’s Q3 FY19 Financial Results
Dr. Reddy’s Laboratories Ltd. today announced its consolidated financial results for the quarter ended December 31, 2018 under International Financial Reporting Standards .
- Reuters•4 months ago
Dr. Reddy's third-quarter profit surges on strong growth in emerging markets
(Reuters) - Indian generic drugmaker Dr. Reddy's Laboratories Ltd posted a 65.3 percent surge in quarterly profit on Friday, handily beating market expectations, helped by strong growth in emerging markets. ...
- Business Wire•4 months ago
Dr. Reddy's Laboratories and Its U.S. Subsidiary, Promius Pharma, Announce FDA Approval for TOSYMRA™ (Sumatriptan Nasal Spray) 10 mg, in the U.S. Market
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) and its subsidiary, Promius Pharma, LLC today announced the approval of TOSYMRA (previously known as DFN-02) by the U.S. Food and Drug Administration (FDA). TOSYMRA is indicated for the acute treatment of migraine with or without aura in adults. TOSYMRA is the latest product to join the Promius Pharma acute migraine treatment portfolio.
- Business Wire•4 months ago
Dr. Reddy's Laboratories Announces the Launch of Propofol Injectable Emulsion, USP in the U.S. Market
Dr. Reddy’s Laboratories Ltd. today announced the launch of Propofol Injectable Emulsion, USP, a therapeutic equivalent generic version of DIPRIVAN Injectable Emulsion, USP, approved by the U.S.
- Business Wire•4 months ago
Dr. Reddy's to Release Q3 FY19 Results on February 1, 2019
Earnings call slated for February 1, 6:30 PM IST / 8:00 AM EST
- Simply Wall St.•4 months ago
What Investors Should Know About Dr. Reddy’s Laboratories Limited’s (NSE:DRREDDY) Financial Strength
Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as Dr. Reddy's Laboratories Limited (NSE:DRREDDY) with a market-capitalization of ₹432b, rarely draw their attention. However, generally ignored Read More...
- Business Wire•4 months ago
Dr. Reddy's Laboratories Limited to Present at the 37th Annual J.P. Morgan Healthcare Conference
Dr. Reddy’s Laboratories Ltd announced that the Company will be presenting at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, California.
- Business Wire•5 months ago
Dr. Reddy's Laboratories Announces the Launch of Sevelamer Carbonate for Oral Suspension in the U.S. Market
Dr. Reddy’s Laboratories Ltd. today announced the launch of Sevelamer Carbonate for Oral Suspension, in 0.8 g and 2.4 g packets, a therapeutic equivalent generic version of Renvela for Oral Suspension, approved by the U.S.
- Business Wire•5 months ago
Dr. Reddy's Laboratories Launches Aspirin and Extended-Release Dipyridamole Capsules in the U.S. Market
Dr. Reddy’s Laboratories Ltd , along with its subsidiaries together referred to as “Dr. Reddy’s”, today announced the launch of Aspirin and Extended-Release Dipyridamole Capsules, a therapeutic equivalent generic version of Aggrenox Capsules in the United States market from the U.S.
- Business Wire•5 months ago
Dr. Reddy’s announces the launch of over-the-counter store brand equivalent of Prilosec OTC® (Omeprazole Delayed-Release) Tablets, 20 mg in the U.S. Market
Dr. Reddy’s Laboratories Ltd. announced today the launch of Omeprazole Delayed-Release Tablets, 20 mg, an over-the-counter store-brand equivalent of Prilosec® OTC Tablets, 20 mg, in the United States market as approved by the U.S.
